Literature DB >> 25367716

Dulaglutide: first global approval.

Mark Sanford1.   

Abstract

Dulaglutide (Trulicity™) is a long-acting, glucagon-like peptide-1 (GLP-1) receptor agonist that has been developed by Eli Lilly and Company for the treatment of type 2 diabetes mellitus. It consists of a dipeptidyl peptidase-IV-protected GLP-1 analogue covalently linked to a human IgG4-Fc heavy chain by a small peptide linker. The subcutaneous formulation is approved for use in type 2 diabetes in the US, has been recommended for approval in the EU in this indication, and is under regulatory review in other countries. This article summarizes the milestones in the development of subcutaneous dulaglutide leading to this first approval for type 2 diabetes.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25367716     DOI： 10.1007/s40265-014-0320-7

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  6 in total

1.  Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.

Authors:  Wolfgang Glaesner; Andrew Mark Vick; Rohn Millican; Bernice Ellis; Sheng-Hung Tschang; Yu Tian; Krister Bokvist; Martin Brenner; Anja Koester; Niels Porksen; Garret Etgen; Tom Bumol
Journal:  Diabetes Metab Res Rev       Date:  2010-05       Impact factor: 4.876

2.  Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

Authors:  Guillermo Umpierrez; Santiago Tofé Povedano; Federico Pérez Manghi; Linda Shurzinske; Valeria Pechtner
Journal:  Diabetes Care       Date:  2014-05-19       Impact factor: 19.112

3.  Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Authors:  Espen Jimenez-Solem; Mette H Rasmussen; Mikkel Christensen; Filip K Knop
Journal:  Curr Opin Mol Ther       Date:  2010-12

4.  Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).

Authors:  Carol Wysham; Thomas Blevins; Richard Arakaki; Gildred Colon; Pedro Garcia; Charles Atisso; Debra Kuhstoss; Mark Lakshmanan
Journal:  Diabetes Care       Date:  2014-05-30       Impact factor: 19.112

5.  Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

Authors:  Kathleen M Dungan; Santiago Tofé Povedano; Thomas Forst; José G González González; Charles Atisso; Whitney Sealls; Jessie L Fahrbach
Journal:  Lancet       Date:  2014-07-10       Impact factor: 79.321

6.  Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

Authors:  Michael Nauck; Ruth S Weinstock; Guillermo E Umpierrez; Bruno Guerci; Zachary Skrivanek; Zvonko Milicevic
Journal:  Diabetes Care       Date:  2014-04-17       Impact factor: 19.112
  6 in total
  3 in total

Review 1.  Revisiting amino acids and peptides as anti-glycation agents.

Authors:  H Chilukuri; M J Kulkarni; M Fernandes
Journal:  Medchemcomm       Date:  2018-02-12       Impact factor: 3.597

2.  Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials.

Authors:  Jeanne S Geiser; Michael A Heathman; Xuewei Cui; Jennifer Martin; Corina Loghin; Jenny Y Chien; Amparo de la Peña
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

3.  A Peptide-Fc Opsonin with Pan-Amyloid Reactivity.

Authors:  James S Foster; Angela D Williams; Sallie Macy; Tina Richey; Alan Stuckey; Daniel Craig Wooliver; Richa Koul-Tiwari; Emily B Martin; Stephen J Kennel; Jonathan S Wall
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.